Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Mar;61(3):445-454.
doi: 10.1194/jlr.P119000473. Epub 2019 Dec 31.

High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia

Affiliations
Randomized Controlled Trial

High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia

Manja Koch et al. J Lipid Res. 2020 Mar.

Abstract

Whether HDL is associated with dementia risk is unclear. In addition to apoA1, other apolipoproteins are found in HDL, creating subspecies of HDL that may have distinct metabolic properties. We measured apoA1, apoC3, and apoJ levels in plasma and apoA1 levels in HDL that contains or lacks apoE, apoJ, or apoC3 using a modified sandwich ELISA in a case-cohort study nested within the Ginkgo Evaluation of Memory Study. We included 995 randomly selected participants and 521 participants who developed dementia during a mean of 5.1 years of follow-up. The level of total apoA1 was not significantly related to dementia risk, regardless of the coexistence of apoC3, apoJ, or apoE. Higher levels of total plasma apoC3 were associated with better cognitive function at baseline (difference in Modified Mini-Mental State Examination scores tertile 3 vs. tertile 1: 0.60; 95% CI: 0.23, 0.98) and a lower dementia risk (adjusted hazard ratio tertile 3 vs. tertile 1: 0.73; 95% CI: 0.55, 0.96). Plasma concentrations of apoA1 in HDL and its apolipoprotein-defined subspecies were not associated with cognitive function at baseline or with the risk of dementia during follow-up. Similar studies in other populations are required to better understand the association between apoC3 and Alzheimer's disease pathology.

Keywords: Alzheimer’s disease; aging; cognition; epidemiology.

PubMed Disclaimer

Conflict of interest statement

The funding sources had no role in study design; in the collection, analysis, and interpretation of the data; in the writing of the report; or in the decision to submit the article for publication. The authors declare that they have no conflicts of interest with the contents of this article.

Figures

Fig. 1.
Fig. 1.
Smoothed means of ADAS-cog scores not censored by death, dropout, or dementia, stratified by tertiles of apoA1 (A) and whole plasma apoC3 (B) concentrations measured at study entry, in the GEMS cohort.

References

    1. Alzheimer’s Association. 2017. 2017 Alzheimer’s disease facts and figures. Alzheimers Dement. 13: 325–373.
    1. Satizabal C. L., Beiser A. S., Chouraki V., Chene G., Dufouil C., and Seshadri S.. 2016. Incidence of dementia over three decades in the Framingham Heart Study. N. Engl. J. Med. 374: 523–532. - PMC - PubMed
    1. Jack C. R. Jr., Bennett D. A., Blennow K., Carrillo M. C., Dunn B., Haeberlein S. B., Holtzman D. M., Jagust W., Jessen F., Karlawish J., et al. . 2018. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14: 535–562. - PMC - PubMed
    1. Olsson B., Lautner R., Andreasson U., Ohrfelt A., Portelius E., Bjerke M., Holtta M., Rosen C., Olsson C., Strobel G., et al. . 2016. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 15: 673–684. - PubMed
    1. Karlawish J., Jack C. R. Jr., Rocca W. A., Snyder H. M., and Carrillo M. C.. 2017. Alzheimer’s disease: the next frontier—special report 2017. Alzheimers Dement. 13: 374–380. - PubMed

Publication types